Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1992 | 1 |
2007 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Regression of kaposiform lymphangiomatosis and chronic disseminated intravascular coagulation after inhaled budesonide-formoterol treatment.
Pediatr Blood Cancer. 2024 Apr;71(4):e30907. doi: 10.1002/pbc.30907. Epub 2024 Jan 31.
Pediatr Blood Cancer. 2024.
PMID: 38296836
No abstract available.
Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies.
Falanga A, Rickles FR.
Falanga A, et al.
Hematology Am Soc Hematol Educ Program. 2007:165-71. doi: 10.1182/asheducation-2007.1.165.
Hematology Am Soc Hematol Educ Program. 2007.
PMID: 18024625
Patients with hematologic malignancies often present with a hypercoagulable state or chronic disseminated intravascular coagulation (DIC) in the absence of active thrombosis and/or bleeding. Malignant cell procoagulant properties, cytotoxic therapie …
Patients with hematologic malignancies often present with a hypercoagulable state or chronic disseminated intravascular …
Item in Clipboard
Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy.
Chan A, Woodruff RK.
Chan A, et al.
Aust N Z J Med. 1992 Apr;22(2):119-22. doi: 10.1111/j.1445-5994.1992.tb02789.x.
Aust N Z J Med. 1992.
PMID: 1530532
Complications of treatment included major bleeding (35%), redevelopment of VTE whilst on therapeutic levels of anticoagulants (13%) and recurrent VTE following cessation of anticoagulant (42%). ...The high incidence of bleeding is frequently associated with over-anticoagul …
Complications of treatment included major bleeding (35%), redevelopment of VTE whilst on therapeutic levels of anticoagulants (13%) a …
Item in Clipboard
Cite
Cite